pramanicin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10595278 |
| CHEBI ID | 179179 |
| MeSH ID | M0395752 |
| Synonym |
|---|
| (3s,4s,5s)-3,4-dihydroxy-5-(hydroxymethyl)-3-[(e)-3-[(2r,3r)-3-nonyloxiran-2-yl]prop-2-enoyl]pyrrolidin-2-one |
| CHEBI:179179 |
| LMSP01080048 |
| pramanicin |
| AKOS040735712 |
Pramanicin (PMC) is an antifungal agent that was previously demonstrated to exhibit antiangiogenic and anticancer properties. PMC has a wide range of potential application against human diseases.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pramanicin (PMC) is an antifungal agent that was previously demonstrated to exhibit antiangiogenic and anticancer properties in a few in vitro studies. " | ( Pramanicin analog induces apoptosis in human colon cancer cells: critical roles for Bcl-2, Bim, and p38 MAPK signaling. Basaga, H; Bodur, C; Harrison, P; Isimjan, TT; Karsli-Uzunbas, G; Kutuk, O, 2013) | 3.28 |
| "Pramanicin is a novel anti-fungal drug with a wide range of potential application against human diseases. " | ( Pramanicin induces apoptosis in Jurkat leukemia cells: a role for JNK, p38 and caspase activation. Basaga, H; Harrison, P; Kutuk, O; Pedrech, A, 2005) | 3.21 |
| Class | Description |
|---|---|
| beta-hydroxy ketone | A ketone containing a hydroxy group on the beta-carbon relative to the C=O group. |
| enone | An alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.36) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||